Plague vaccine intranasal - ID Biomedical/USAMRMC
Alternative Names: Yersinia pestis vaccine intranasal - ID Biomedical/USAMRMCLatest Information Update: 27 Jun 2007
At a glance
- Originator ID Biomedical Corporation; United States Army Medical Research and Materiel Command
- Class Plague vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pneumonic plague
Most Recent Events
- 27 Jun 2007 Discontinued - Preclinical for Pneumonic plague in USA (Intranasal)
- 08 Dec 2005 ID Biomedical Corporation has been acquired by GlaxoSmithKline
- 23 Sep 2004 ID Biomedical was awarded up to US$8 million from the US NIH to develop a nasally delivered plague vaccine based upon the ID Biomedical's Proteosome™ technology